RARE stock forecast
Our latest prediction for Ultragenyx Pharmaceutical, Inc.'s stock price was made on the Sept. 11, 2019 when the stock price was at 45.01$.
In the short term (2weeks), RARE's stock price should outperform the market by 3.31%. During that period the price should oscillate between -7.98% and +11.18%.
In the medium term (3months), RARE's stock price should outperform the market by 2.50%. During that period the price should oscillate between -19.05% and +27.37%.Get email alerts
About Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
At the moment the company generates 84M USD in revenues.
On its last earning announcement, the company reported a loss of -7.25$ per share.
The book value per share is 14.03$
Three months stock forecastSept. 11, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|